[{"orgOrder":0,"company":"Caring Brands","sponsor":"D. Boral Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Minoxidil","moa":"Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Caring Brands","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Caring Brands \/ D. Boral Capital","highestDevelopmentStatusID":"15","companyTruncated":"Caring Brands \/ D. Boral Capital"}]

Find Clinical Drug Pipeline Developments & Deals by Caring Brands

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ISPOR Europe 2025
                          Not Confirmed
                          ISPOR Europe 2025
                          Not Confirmed

                          Details : The proceeds from the offering will be used to fund the clinical development of Minoxidil for hair loss targeting Sulfonylurea receptor 2 and Kir6.2.

                          Product Name : Hair Enzyme Booster

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          November 14, 2025

                          Lead Product(s) : Minoxidil

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : D. Boral Capital

                          Deal Size : $4.0 million

                          Deal Type : Public Offering

                          blank